Dynamic Modeling and Stochastic Simulation of Metabolic Networks

Emalie J. Clement¹, Ghada A. Soliman², Beata J. Wysocki¹, Paul H. Davis¹, Tadeusz A. Wysocki^{3,4}.

¹Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USA.

²Graduate School of Public Health and Health Policy, City University of New York, New York, USA.

³Department of Electrical and Computer Engineering, University of Nebraska – Lincoln, Omaha, Nebraska, USA.

⁴UTP University, Bygoszcz, Poland.

*Corresponding author

Email: pdavis@unomaha.edu (PHD)

All authors contributed equally to this work.

16 Abstract

17 Increased technological methods have enabled the investigation of biology at nanoscale levels.
 18 Nevertheless, such systems necessitate the use of computational methods to comprehend the complex
 19 interactions occurring. Traditionally, dynamics of metabolic systems are described by ordinary differential
 20 equations producing a deterministic result which neglects the intrinsic heterogeneity of biological systems.
 21 More recently, stochastic modeling approaches have gained popularity with the capacity to provide more
 22 realistic outcomes. Yet, solving stochastic algorithms tend to be computationally intensive processes.
 23 Employing the queueing theory, an approach commonly used to evaluate telecommunication networks,
 24 reduces the computational power required to generate simulated results, while simultaneously reducing
 25 expansion of errors inherent to classical deterministic approaches. Herein, we present the application of
 26 queueing theory to efficiently simulate stochastic metabolic networks. For the current model, we utilize
 27 glycolysis to demonstrate the power of the proposed modeling methods, and we describe simulation and
 28 pharmacological inhibition in glycolysis to further exemplify modeling capabilities.

30 Author Summary

31 Computational biology is increasingly used to understand biological occurrences and complex
 32 dynamics. Biological modeling, in general, aims to represent a biological system with computational
 33 approaches, as realistically and accurate as current methods allow. Metabolomics and metabolic systems
 34 have emerged as an important aspect of cellular biology, allowing a more sensitive view for understanding
 35 the complex interactions occurring intracellularly as a result of normal or perturbed (or diseased) states. To
 36 understand metabolic changes, many researchers have commonly used Ordinary Differential Equations to
 37 produce *in silico* models of the *in vitro* system of interest. While these have been beneficial to date,
 38 continuing to advance computational methods of analyzing such systems is of interest. Stochastic models
 39 that include randomness have been known to produce more realistic results, yet the difficulty and intensive
 40 time component urges additional methods and techniques to be developed. In the present research, we

41 propose using queueing networks as a technique to model complex metabolic systems, doing such with a
42 model of glycolysis, a core metabolic pathway.

43

44 **Introduction**

45 Cellular metabolism is an extensively complex network of enzymes, metabolites and other
46 biomolecules required to both maintain homeostasis and appropriately react to stimuli. Biochemists began
47 examining cell metabolism in the mid-19th century, and with our advancement in both experimental
48 techniques and computational capacity, increasing comprehension of metabolic intricacies has been
49 realized. As a relatively new field, metabolomics studies are concerned with the detection and
50 quantification of metabolites. When considering the complexity of the metabolome, the analytical side of
51 metabolomics and metabolism can easily become daunting. The KEGG Compound database currently
52 contains 18,047 metabolites and other small molecules, making the intuitive aspect of understanding
53 metabolite dynamics nearly inconceivable [1]. Thus, computational modeling reconstruction and simulation
54 of metabolic systems have become pivotal in the analysis and surveillance of such systems.

55 Within the last decade, it has been a considerable goal to develop mathematical models of
56 biological systems that accurately predict cellular and ultimately systems level behavior, providing
57 quantitative details and prediction of phenotypic changes resulting from perturbation. Models as a whole
58 are a representation of reality, aiming to accurately represent the system of study. Inclusion of all cellular
59 components indirectly or directly involved are considered far too complex to model. Consequently,
60 simplifications and assumptions must be made and often the perceived non-pivotal details, such as
61 stochasticity, omitted. Nevertheless, the accuracy and competence of the model is dependent on these
62 assumptions and simplifications.

63 Many approaches may be taken to model the dynamics of metabolic systems; importantly, the
64 categorization of deterministic and stochastic modeling approaches. Most often, kinetic models of
65 metabolism have been modeled using ordinary differential equations (ODE) providing a deterministic

66 modeling approach that gives quantitative information on the interactions, underlying dynamics, and
 67 regulation of the components of the system [2]. ODE models operate with the assumption that all reactions
 68 occur under evenly mixed, homogenous populations with many molecules in the environment. From early
 69 on, ODEs have been used to simulate biochemical kinetics and biochemical networks. This approach, with
 70 historically “limited” computational power, was sufficient to describe the interactions and dynamics
 71 occurring within biochemical networks. Rapoport et al. describes the ability to determine metabolite
 72 concentrations of glycolytic intermediates in erythrocytes by a desktop calculator [3]. In our current time,
 73 with the aid of increasing computational power, metabolite concentrations within an enzymatic chain of
 74 reactions can be determined almost instantly. There are numerous methods and well defined strategies for
 75 solving ODEs; the prevalence and significance in both biochemical simulations in addition to mathematics
 76 offer a firm grasp on dealing with simple systems of ordinary differential equations. While ODE modeling
 77 reduces computational efforts, the assumptions and simplifications come at the cost of omitting noise and
 78 randomization that is inherent in biological systems. Thus, stochastic modeling approaches may be a more
 79 realistic representation of *in vitro* and *in vivo* systems [2].

80 Though ODE methods have been well defined in biological community, more recently, systems
 81 biology has begun to extend the limits of what has previously been capable computationally; modeling the
 82 complexities of biological variation - the stochastic effects inherent in biology. Stochastic models are
 83 typically formulated by the chemical master equation (CME), and have the ability to capture the stochastic
 84 occurrences common in biological systems. Yet, the drawback comes with the increased mathematical and
 85 computational complexity, additionally limiting the size of the network. The CME is a continuous Markov
 86 process that has commonly been handled by way of Monte-Carlo simulations, wherein the probability of a
 87 particular reaction occurring is calculated and the probability of the particular reaction occurring in a given
 88 time interval is also calculated and updated given the state of the system [4]. Needless to say, the
 89 complexity of even a small system becomes unmanageable. Not to mention the increase in the number of
 90 parameters required and whether or not the specific parameters are appropriate given the context in which

91 they are derived [5]. The Gillespie algorithm, introduced in 1977, provides exact simulation methods and
 92 can be sped up with the implementation of Tau leaps [4,6,7]. Still, attempts are being made to improve
 93 stochastic simulation, and overcome the difficulties involved [2,5,8–13].

94 One relatively new approach to understanding and modeling complex biological networks is the
 95 application of queueing networks. Having some similarities to the Gillespie algorithm, queueing networks
 96 can be represented as a Markov chain, being more convenient to use than directly implementing the
 97 Gillespie algorithm [14]. Queueing networks have previously been used to describe data communication
 98 networks [15], servicing of patients at hospitals [16], the HIV infection process [17], pharmacokinetic
 99 modeling [18], and non-viral gene delivery [19]. Moreover, the implementation as described by Martin et
 100 al. [19], has accounted for other cell processes, like mitosis or cell necrosis, which are not easy to
 101 implement in the ODE approach. Queuing networks have also been used to develop a simple model of
 102 metabolism [20] and enzyme substrate interactions [21]. Briefly, queueing theory is a method of
 103 approaching stochastic simulations, doing so in such a way that computationally, it is less intensive and
 104 accordingly, possesses the ability to potentially describe larger networks - large networks that may not be
 105 able to be simulated in a reasonable amount of time given other stochastic simulation methods.

106 Recently, we have developed a tool to recapitulate observed *in vitro* insulin responses, plus measure
 107 the effects of Wortmannin-like inhibition on glucose uptake [22]. This has provided insight into transient
 108 changes in molecule concentrations throughout the insulin signaling pathway, and opened the door to
 109 identify critical, drug-targetable components of this pathway, including those associated with insulin
 110 resistance. Notably, our model was capable of calculating all network components of 100 averaged cells at
 111 near real-time: approximately 12 minutes on a desktop computer to produce 10 minutes of simulated data.
 112 Comparatively, the classical ODE approach of this complex network was calculated to take more than 80
 113 days for completion. More importantly, though, the classical approach fails to take into account random
 114 variation naturally occurring within cells and tissues [23]. Conversely, the application of queueing theory
 115 has recently provided the ability to overcome computational intensity and incorporate a natural variation of

kinetic constants and initial molecular concentrations. Herein, we present the current model using queueing theory to simulate the stochastic effects of glucose metabolism as a simplified technique to model metabolism, specifically glucose metabolism. For model validation, we provide qualitative comparisons of pharmacological inhibition in both simulated conditions and experimental metabolic data from cancer cells.

120

121 **Methods**

122 The model presented uses ODE's and glucose metabolism as a platform to describe the dynamical
123 behavior of the pathway. Glucose metabolism has been described with ODEs in many modeling efforts.
124 Being well defined both computationally and biochemically, researchers often model glycolysis and
125 glucose metabolism when developing novel simulation methods. With a predetermined notion of the
126 outcome, one can more easily compare results and begin validating the computational methods being
127 developed. Consequently, we have used glycolysis to present queueing theory modeling of metabolic
128 networks. A brief overview of glycolysis and glucose metabolism can be found in [24].

129 For the initial development of the model, we made use of previously derived mechanistic equations
130 employing Michaelis-Menten kinetics. The mathematical analysis of the rate equations and parameters used
131 are described in Mulukutla et al [25]. The derivation of the rate equations can be found in Mulquiney et al. .
132 Our aim was to use a previously defined model to implement our proposed queueing theory approach, thus
133 the parameters and kinetic constants for the current model were chosen to reflect the model investigated in
134 Mulukutla et al. Notably, Mulquiney et al. report experimental and observed initial metabolite
135 concentrations which were used for the current model. Concentration and parameter values that were either
136 absent or substantially different between sources were obtained through additional literature searches .
137 Furthermore, energy nucleotides and metal ions were fixed in our model for simplification and to centralize
138 the model around the intermediate metabolites of glycolysis. Table 1 lists the initial concentrations of the
139 metabolites measured in the simulation output, while Table 2 provides concentrations of additional
140 substrates that were required for calculations, but not directly measured throughout the simulation.

To demonstrate the mechanics of how queueing networks are applied to modeling metabolic

pathways, one can consider a pathway of N interacting metabolites $M_1, \dots, M_N$ having initial concentrations

at time instant t_0 of $C_1(t_0), \dots, C_N(t_0)$. Within the considered metabolic pathway, each of the metabolites $M_1,$

$\dots, M_N$ is involved in K_i reactions, $i = 1, \dots, N$. The corresponding reaction rates $v_{i,j}(C_1(t), \dots, C_N(t), t); i =$

$1, \dots, N; j = 1, \dots, K_i$, usually depend on the instantaneous concentrations of the interacting metabolites at

time t , as well as other metabolites/enzymes, which given the time variability of those, is denoted as

additional time dependability of t . The reaction rates can be positive or negative, with metabolites being

produced for the positive sign and absorbed if the sign is negative. To find the concentration of the

particular metabolite, $C_i(t)$ at given time instant t , one normally needs to solve a set of ODEs of the form:

$$\frac{d}{dt}C_1(t) = \sum_{j=1}^{K_1} v_{1,j}(C_1(t), \dots, C_N(t), t)$$

$$\frac{d}{dt}C_2(t) = \sum_{j=1}^{K_2} v_{2,j}(C_1(t), \dots, C_N(t), t)$$

....

$$\frac{d}{dt}C_N(t) = \sum_{j=1}^{K_N} v_{N,j}(C_1(t), \dots, C_N(t), t)$$

with the initial condition $C_1(t_0), \dots, C_N(t_0)$.

Given the interdependency of the concentrations $C_1(t_0), \dots, C_N(t_0)$, which is usually highly non-

linear, and further dependency of other time varying and/or random factors, achieving the solution of such

sets of equations is not only extremely computationally intensive, but also not guaranteed to produce a

numerically stable result. The problem is further complicated by the fact that the concentrations $C_1(t), \dots,$

$C_N(t)$ are always non-negative, and as reported by Infante et al [30], and Erbe et al.[31], this is a non-trivial

task or such a solution may not even exist. One can force the numerical solver to produce the non-negative

(1)

165 solution, for example by using MATLAB's 'NonNegative' option is in the 'odeset' solver [32]. However,
 166 this significantly increases the computation time, and the solution may not be accurate or numerically
 167 stable. This might be especially problematic for those metabolites that are not expressed in high
 168 concentrations and/or are very rapidly used in other reactions, for example, the metabolite glucose-6-
 169 phosphate (G6P) is also an intermediate in the Pentose Phosphate Pathway (PPP) and glycogen metabolism
 170 [33].

171 To find a method to simulate processes described by the set of ODEs (1), one can notice that each
 172 of the ODEs in (1) is of the form describing an average behavior of an $M(t)/M(t)/c$ non-depleting queue
 173 [14]. In general, the $M(t)/M(t)/c$ queue is such a system where arrivals form a single queue and are
 174 governed by a time varying Poisson process, there are c servers and job service times are exponentially
 175 distributed with time varying rates. The $M(t)/M(t)/c$ non-depleting queues are special cases of queues [16]
 176 where for each time interval, the difference between corresponding arrival rate and service rate is non-
 177 negative. Massey et al [14] also analyzed a general case of $M(t)/M(t)/c$ queues, for which there is no simple
 178 method to describe them by means of ODEs, but which can be depleted to zero elements in the queue or in
 179 other words for queues that can be completely emptied.

180 Hence, the $M(t)/M(t)/c$ queues can be used to model metabolic pathways for simulation purposes,
 181 and instead of solving a set of ODEs (1), simulate a network of interconnected $M(t)/M(t)/c$ queues,
 182 provided that the concentrations $C_1(t), \dots, C_N(t)$ are digitized. The arrival rates are for the queues and the
 183 service rates are the reaction rates $v_{i,j}(C_1(t), \dots, C_N(t), t)$ normalized to the duration of a single simulation
 184 time step Δt_i and the concentration increment $\Delta(C_i(t))$, which denotes a finite change of $C_i(t)$ in time
 185 increment of Δt_i . The normalization is done according to the formula:

$$\mu_{i,j} = \frac{v_{i,j}(C_1(t), \dots, C_N(t), t)\Delta t_i}{\Delta(C_i(t))} \quad (2)$$

If the normalized rate $\mu_{i,j}$ is positive, it is an arrival rate while if it is negative it is a service rate. The instantaneous length of each queue provides a possible realization of a stochastic Markovian process representing variations of concentration of the given metabolite. Of course, the average changes in concentration can be achieved by averaging the simulation results for several simulation runs. To ensure correctness of simulation, the simulation time step Δt_i and the concentration increment $\Delta(C_i(t))$, have to be chosen in such a way that all $\mu_{i,j}$ are lower than 1, as the arrival and service rates represent the probabilities of arrival and service of $\Delta(C_i(t))$ in the given time interval. It should be noted that for ensuring that just a single $\Delta(C_i(t))$ is processed in each time interval the conditions are as follows:

$$\begin{aligned} \mu_{i,j} &< 1, \\ \text{for } j &= 1, \dots, K_i \text{ and } i = 1, \dots, N \end{aligned} \tag{3}$$

However, neither the simulation time step Δt_i nor the concentration increment $\Delta(C_i(t))$, do not need to be the same for all $i = 1, \dots, N$, but can be chosen in a way that minimizes the simulation time, while ensuring that the condition (3) is satisfied. Though the time increment can be calculated dynamically within each step, for the current model we have chosen a constant time increment to speed up simulation time. Given the stochastic nature of chemical reactions, where the reaction rates can vary depending on environmental conditions, the reaction rates can be randomized by adding the Gaussian (or other) noise to the kinetic constants used to calculate values of $v_{i,j}(C_1(t), \dots, C_N(t), t)$. The same can be performed for the initial concentrations at time instant t_0 of $C_1(t_0), \dots, C_N(t_0)$.

A queue representing concentration of a single metabolite is shown in Fig 1, where the inputs to the represent reactions leading to production of the metabolite and outputs represent reactions using this metabolite. The cloud connected to the queue via bi-directional arrow represents processes not considered (or not even currently discovered) that result in an imbalance between an aggregated input to- and an aggregated output from the queue. The arrivals to the queue, representing discrete increments in

concentration of the metabolite are modeled as Poisson processes, while the service time (time intervals between two consecutive output events) is modeled by an exponential distribution. Assuming that in total there are c -outputs from the queue, the queue can be considered as a standard $M(t)/M(t)/c$ queue, as described before.

Fig 1. Example Queue.

Queue representing concentration $C_i(t)$ of the metabolite M_i ; $\mu_{i,j}$, $j = 1, \dots, L_i$, are arrival rates as corresponding to processes resulting in production of metabolite M_i ; $\mu_{i,j}$, $j = L_i + 1, L_i + 2, \dots, K_i^*$, are service rates corresponding to processes using metabolite M_i . K_i^* = number of reactions considered in the model metabolite M_i is involved in.

For the description to be valid, the sums of all arrival rates, $\mu_{i,j}$, $j = 1, \dots, L_i$, and the sum of all service rates $\mu_{i,j}$, $j = L_i + 1, L_i + 2, \dots, K_i^*$ must each be lower than 1. A fulfilment of this condition can be satisfied by either reducing the duration of time increment or increasing the concentration unit. Of course, reducing the time increment increases the simulation time, as more simulation steps must be considered for the duration of an experiment, while increasing the concentration unit may reduce the accuracy of the simulation results. Therefore, a careful balance must be struck while choosing those parameters. Furthermore, from the perspective of implementing simulation of the metabolic process, it is convenient to ensure that in a given simulation step only one concentration unit of a given metabolite M_i is going to be processed. Assuming that there are $J_i = K_i^* - L_i$ possible reactions that can be utilizing metabolite M_i , the probability P_{i1} that this happens is given by the formula:

$$(4)$$

$$P_{i1} = \sum_{j=1}^{J_i} \mu_{i,j} \prod_{\substack{k=1 \\ k \neq j}}^{J_i} (1 - \mu_{i,k})$$

and the conditional probability $P_{i\{j|1\}}$ that if just one concentration unit is processed in a particular simulation step, it is processed in reaction associated with reaction rate $\mu_{i,j}$, is given by:

238 (5)

$$239 \quad P_{i|j|1} = \frac{\mu_{i,j}}{(1 - \mu_{i,j}) \sum_{k=1}^J \frac{\mu_{i,k}}{(1 - \mu_{i,k})}}$$

240

241 It is important to notice here that metabolomics data often include missing or semi-quantitative data,

242 and some connections between the metabolites might have not been discovered, yet. To account for those

243 unknown or missing reactions, an additional input/output pathway is included in the model for every

244 metabolite considered, and shown in Fig 1 as a dashed line connection, which can be bi-directional. The

245 rate μ_i^* is to be determined as the rate balancing the steady state value of the concentration $C_i(t)$. If the rate

246 μ_i^* is positive, then for a corresponding metabolite concentration different from the steady state value, the

247 rate is scaled by a factor equal to the ratio of the actual concentration to the concentration at the steady

248 state. If it is negative, the scaling is inversely proportional. As previously mentioned, we have used

249 queueing theory to describe additional biological pathways. In such, [34,35] provide further explanations of

250 the proposed queueing theory methods. Additionally, pseudocode of the queueing theory application has

251 been provided in the appendix section.

252

253 Results

254 For the current study, our interest was in the ability to mechanistically model enzymatic reactions

255 and stochastically simulate the dynamics of glycolysis utilizing queues. In general, queueing theory is a

256 mathematical tool used to describe, model and analyze waiting lines, or queues [36]. At cellular level,

257 metabolites are produced, absorbed, or used by cellular processes, thus forming “queues” of metabolites.

258 Production or absorption of the metabolite adds to the appropriate queue length, and usage of the

259 metabolite reduces the queue length. Both production and usage of a given metabolite are described by

260 discrete random processes, referred to as an arrival and service process, respectively[37]. The queues can

261 be easily interconnected, and as such are ideally suited to model metabolic networks, the same way as they

are used to model the Internet [15]. Our previous work shows the ability to accurately simulate conditions seen *in vivo* using a fraction of the computing power of classical quantitative approaches at the time [22]. We have adjusted our queuing theory-based approach to model metabolic pathways given mechanistic rate equations of all glycolytic reactions and validated experimental metabolite data. As a core metabolic pathway common to all lifeforms, glycolysis is the enzymatic breakdown of glucose into a usable form of energy, additionally supplying intermediate metabolites as “building blocks” for connecting pathways to further support life. Naturally, glycolysis provides a scaffold to begin extending our model to incorporate additional metabolic pathways.

For the initial development of the model, we made use of previously derived mechanistic equations employing Michaelis-Menten kinetics. For the model simulations, all intermediate metabolites were represented by different queues, as described in the methods section. Additionally, the queues representing metabolites have been connected if there is a reaction converting one metabolite into another. Fig 2 shows the assembled queueing network representing glycolysis from glucose to pyruvate; where GLC, glucose; G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; F16BP, fructose 1,6-bisphosphate; F26BP, fructose 2,6-bisphosphate; GAP glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate; 13BPG, 1,3-bisphosphoglycerate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate; PYR, pyruvate.

Fig 2. Simulated metabolic pathway from glucose to pyruvate.

Arrows denote the modeled reactions. V_i , $i = 0, \dots, 10$, and $V3A$, $V3B$, are the reaction rates; for bidirectional arrows the direction is determined by the sign of the corresponding reaction rate with the positive direction being from the top down. GLC, glucose; G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; F16BP, fructose 1,6-bisphosphate; F26BP, fructose 2,6-bisphosphate; GAP glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate; 13BPG, 1,3-bisphosphoglycerate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate; PYR, pyruvate.

For the stochastic simulations presented, the rate equations and model parameters were used as they are indicated in the literature (Table 1 and Table 2). Highlighting the significance of the approach, the current methods enabled rapid alteration of parameter adjustment and additional simulations under a variety of selected *in silico* conditions. Due to the rapid catalytic conversion 3-PG and 2-PG in combination with the low metabolic concentrations, as separate queues the metabolites 3-PG and 2-PG were readily depleted given the 1 microsecond time scale used for the metabolite calculations. Thus, 3-PG and 2-PG were grouped in a single queue avoiding the occurrence of complete deficiency. Furthermore, the summation of the two consecutive metabolites within a queue slightly decreases total calculations and consequently, simulation time.

As previously noted biochemical reactions, and biological system, in general, are inherently stochastic processes. Consequently, randomness and variation were incorporated to add additional stochastic elements to the model simulations. Reaction rates were randomized during simulation by adding an arbitrarily chosen 10% Gaussian noise to the kinetic constants used to calculate values of $v_{i,j}(\cdot)$. The same was performed for the initial concentrations at time instant t_0 of all glycolytic intermediates. During the simulations, each simulated cell is calculated independently; that is, concentrations of each molecule in the metabolic network is stochastic, and bound by error values listed in the literature. The queueing theory approach causes the actual concentrations of given molecule types to be simulated as separate queues within each cell. The probability of a movement happening at any time slice from one queue to the next is determined by the relevant reaction speed. Movements between storages happen at a particular time instant if a number randomly drawn from the interval $[0,1]$ at that time instant is smaller than the reaction speed governing the movement. After simulations have been performed for every considered cell, the results are averaged over the cell population. Variations of 10% glucose levels are randomly computed for every simulated second. The simulations were run with a 1 microsecond time step, and random variations in the values of kinetic constants used in calculating reaction rates were introduced every second. Initial concentrations were randomized by adding 10% Gaussian noise.

311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335

Glycolytic Flux

Previously, Mulukutla et al. aimed to assess the control of different isoforms of the three rate limiting glycolytic enzymes on overall pathway flux behavior. The rate limiting enzymes of glycolysis, hexokinase (HK), phosphofructokinase (PFK), the bifunctional enzyme phosphofructokinase-2/ fructose 2,6-bisphosphatase (PFKFB), and pyruvate kinase (PK) each have multiple isoforms and may be expressed in combination within single cell in a cell-type dependent manner. We considered regulatory mechanisms of PFK, PFKFB, and PK by including parameters and terms in the rate equations to consider the feedback inhibition and activation, keeping both upper and lower glycolytic regulatory loops active in our simulations. The feedback considered consists of F26BP (an important activator of glycolytic flux) and F16BP activation of PFK, F16BP activation of PK, and PEP inhibition of PFKFB activity. The parameters set to simulate the feedback loops are as follows: $K_{PFKf16bp}=0.65$ mM and $K_{PKf16bp}=0.04$ mM. The PFKFB kinase/phosphatase (K/P) ratio, the ratio between the kinase and phosphatase activity, was set to 0.1 by adjusting the value of the PFKFBPase V_{max} leaving the kinase V_{max} at its original value. Different K/P ratios are given in the literature based on specific tissue and cell type. The range varies from less than 1 to 710 depending on the isoform of PFKFB expressed and the tissue type in which it is found. Notably, PFKFB is highly dependent on signaling and hormonal regulation, which can transiently change the K/P ratio given the stimulus. Signaling regulation was not considered in this model, though this component is of interest for further study. Thus, we aimed to keep F26BP relatively constant throughout the initial steady state testing to keep the flux toward a stable level. We found that the K/P ratio of 0.1 kept F26BP and all other metabolites constant over time, the given the parameters used. Therefore, the 0.1 K/P ratio was used to further test the ability of the model to simulate metabolite changes. Simulations were repeated for 30 cells, once completed, the average concentrations of each metabolite per cell were graphed as a function of time (Fig 3).

Fig 3. Steady state glycolytic flux.

Metabolite concentrations were simulated with an input of 5 mM glucose over the course of 1200 seconds to model an unperturbed and constant state.

GAPDH Inhibition

In vitro experiments and model simulations were performed to assess the performance of the proposed queueing approach. FK866 is a non-competitive inhibitor of Nicotinamide phosphoribosyl transferase (NAMPT), the enzyme that supplies the majority of the intracellular pool of NAD⁺, a required substrate for the GAPDH reaction. Extensive research has been performed analyzing the effects of FK866 on high glycolytic flux in cancer cells [38–41]. Under limited NAD⁺ concentrations, the GAPDH reaction represents a bottleneck in glycolysis producing a block in the glycolytic flux. Experimental results show the upper level glycolytic metabolites, including G6P, F6P, F16BP, GAP and DHAP accumulate while the lower metabolites, 13BPG, 3PG/2PG, PEP, and PYR, decrease as substrates become unavailable. Thus, we hypothesized that with the reduction of GAPDH activity and consequently simulation of enzyme inhibition *in silico*, the model should be able to mimic the qualitative metabolic trends seen *in vitro*. Notably, kinetics and enzyme concentrations for the specific cancer cell lines were unknown, therefore, to account for the differences between the cancerous and non-cancerous simulations, the reaction rates were scaled (See Supplementary file S5). The effects of FK866 are presented in the experimental data provided by [40] in Figs 4, 6, 8 and 10, and by the present model outcomes of GAPDH activity inhibition in Figs 5, 7, 9 and 11.

Fig 4. Effects of FK866 on G6P and F6P concentrations in vitro.

Experimental metabolomics data measuring G6P and F6P concentrations with the inhibitor FK866 in (solid blue and dashed green lines) A2780 and (red) HCT116 cancer cells.

Fig 5. Effects of GAPDH Inhibition on G6P and F6P concentrations in silico.

Simulation of the dynamics of glucose 6-phosphate (G6P) and fructose 6-phosphate (F6P) with the inhibition of Glyceraldehyde phosphate dehydrogenase (GAPDH). The V_{max} of GAPDH was set at 0, 25,

361 50, 90, 95, 97, 98, 99, and 100 percent of its initial value in separate model simulations to simulate varied
362 levels of pharmacological inhibition on the enzyme.

363 **Fig 6. Effects of FK866 on FBP concentrations in vitro.**

364 Experimental metabolomics data measuring fructose 1,6-bisphosphate concentrations with the inhibitor
365 FK866 in (solid blue and dashed green lines) A2780 and (red) HCT116 cancer cells.

366 **Fig 7. Effects of GAPDH Inhibition on FBP concentrations in silico.**

367 Simulation of the dynamics of fructose 1, 6-bisphosphate (FBP) with the inhibition of Glyceraldehyde
368 phosphate dehydrogenase (GAPDH). The Vmax of GAPDH was set at 0, 25, 50, 90, 95, 97, 98, 99, and
369 100 percent of its initial value in separate model simulations to simulate varied levels of pharmacological
370 inhibition on the enzyme.

371 **Fig 8. Effects of FK866 on G6P and F6P concentrations in vitro.**

372 Experimental metabolomics data measuring GAP and DHAP concentrations with the inhibitor FK866 in
373 (solid blue and dashed green lines) A2780 and (red) HCT116 cancer cells.

374 **Fig 9. Effects of GAPDH Inhibition on GAP and DHAP concentrations in silico.**

375 Simulation of the dynamics of glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate
376 (DHAP) with the inhibition of Glyceraldehyde phosphate dehydrogenase (GAPDH). The Vmax of GAPDH
377 was set at 0, 25, 50, 90, 95, 97, 98, 99, and 100 percent of its initial value in separate model simulations to
378 simulate varied levels of pharmacological inhibition on the enzyme.

379 **Fig 10. Effects of FK866 on PEP concentrations in vitro.**

380 Experimental metabolomics data measuring G6P and F6P concentrations with the inhibitor FK866 in (solid
381 blue and dashed green lines) A2780 and (red) HCT116 cancer cells.

382 **Fig 11. Effects of GAPDH Inhibition on PEP concentrations in silico.**

383 Simulation of the dynamics of phosphoenolpyruvate (PEP) with the inhibition of Glyceraldehyde
384 phosphate dehydrogenase (GAPDH). The Vmax of GAPDH was set at 0, 25, 50, 90, 95, 97, 98, 99, and

100 percent of its initial value in separate model simulations to simulate varied levels of pharmacological inhibition on the enzyme.

GAPDH activity was reduced by adjusting the V_{max} of the reaction catalyzed by GAPDH. Inhibition was simulated at 0%, 25%, 50%, 90%, 95%, 97%, 98%, 99%, 100% GAPDH activity, with each inhibitory level run as a separate simulation for a cell population of 30. The simulated results of GAPDH inhibition of G6P+F6P, F16BP, GAP+DHAP, and PEP, are plotted as dose response curves in Figs 5, 7, 9 and 11 to reproduce the effect of metabolite changes from experimental (Figs 4, 6, 8 and 10) pharmacological inhibition of two cancerous cell lines. The FK866 inhibitor concentrations used in both A2780 ovarian and HCT116 colorectal cancer cell lines *in vitro*, were compared to *in silico* reduction of the percent GAPDH activity. Of note, we are making the assumption that at the lowest FK866 concentration (0.3 nM) used *in vitro* did not inhibit GAPDH activity, whereas the highest inhibitor concentrations (40 nM) used completely inhibit its forward catalytic activity since the degree of inhibition corresponding to an exact inhibitor dosage is not reported. Thus, for the present comparisons we aimed to observe the qualitative metabolite changes within the experimental and simulated data, noting complications in making rigorous quantitative comparisons.

F16BP and PEP were measured reported as individual metabolites in the two cancer cell lines, A2780 and HCT116. The comparison of the simulated and experimental data is presented in Figs 6-7 and 10-11. Because of the difficulties in distinguishing isobaric metabolites from one another, G6P+F6P and GAP+DHAP were grouped in the experimental data, and the sum of these metabolites are reported. The model is able to determine the individual metabolite concentrations, however, following each simulation the two metabolites from the model data (G6P+F6P and GAP+DHAP) were added for a closer comparison to the experimental data. Moreover, the data was normalized so that each experiment (*in vitro* and *in silico*) began with the same metabolite concentration, again for a clearer comparison of the actual changes occurring as FK866 doses increased (experimental) and as GAPDH inhibition increased (model simulations).

In silico, we observed increases in all upper glycolytic metabolites with inhibition of GAPDH, supporting the metabolic data of NAMPT inhibition. The lower glycolytic metabolite, PEP shows reduction following increased inhibition of GAPDH, in agreement the results seen in the experimental data. Using a K/P ratio of 0.1, F26BP was the only metabolite that did not change mean values over time throughout the course of GAPDH inhibition at any level. Notably, the experimental data shows a fairly wide range of metabolite concentrations with similar inhibitor doses, between and even within both cell lines. For example, the G6P+F6P concentration in the HCT116 cell line increased from 0.052 mM to 0.512 mM with the highest FK866 treatment, and in the two separate experiments with the A2780 cells the metabolite concentrations increased to only 0.18 mM and 0.13 mM (Fig 4). Again, the aim for the inhibition simulations was to observe the overall trend of metabolite changes, meant for a qualitative comparison. There are slight variations from the experimental data and the model data. Still the results are similar or within range of the experimental data; in the model simulation the F16BP concentration increased from 0.0022 mM to 0.0548 mM at the highest inhibition level, while the F16BP concentration in the HCT116 cell line rose from 0.0022 mM to 0.0496 mM at the highest FK866 treatment (Figs 6-7). Specific kinetics and prior knowledge of experimental data may only aid in reproducing even more consistent results in the future.

The glycolysis model was additionally simulated in the SimBiology app in MatLab using the ode15s solver [32]. The rate equations, parameters and initial concentrations were identical to those used in the queueing theory model in the steady state simulation. When running the simulations, the metabolites reached steady state levels up to 10 seconds. Following the 10 second mark, however 2PG and 3PG progressed to positive infinity and negative infinity, respectively. Moreover, many metabolites had negative concentration values in the steady state simulations. The compiled SimBiology ode15s solver was easy to both operate and simulate deterministic outcomes quickly, however the simulation produced unstable and negative values. As mentioned in the methods section, queueing theory modeling ensures positive concentrations, a clear benefit when attempting to track metabolite or biological species concentration

changes. In the uncompiled version, the current queueing theory model was able to complete 20 minutes of simulation time for 30 cells in roughly two hours.

437

438 **Conclusion**

439 The paper presents a pathway model of glycolysis as a queueing network, a modeling approach
440 widely used in modeling telecommunication packet networks. Dynamic modeling of biological systems,
441 while exceptionally useful poses certain limitations computationally and in reproducing observed
442 phenotypic changes. The application of queueing theory in dynamical modeling may offer a method to
443 overcome such limitations. The current applications of this work hold significant promise for advancing
444 computational biology and biochemical research. The queueing theory represents a mainstay modeling
445 approach of telecommunication networks with application to simulate intracellular metabolism. By viewing
446 enzymes as “gates” and their substrates as “packets,” we have reduced the computational complexity of the
447 simulation to the advantage of much more rapid calculation. Moreover, we have shown previously that we
448 can model intracellular mechanisms and do so while simulating the random variation which exists between
449 and within living cells.

450 Research and experimental techniques in metabolomics have rapidly evolved since its introduction.
451 Modeling strategies must also be able to be adaptable to accommodate novel information and amend the
452 data as needed. The modularity of queues incorporated provides a suitable approach for further model
453 extension, whether that be additional metabolic reactions, parameter refinement, or multi-scale modelling
454 approaches. Moreover, this approach enables the ability to simulate biochemical reactions stochastically
455 without the need to implement or solve stochastic algorithms. As seen above, GAP and DHAP were
456 represented experimentally as a combination of metabolic intermediates, due to their chemical similarities.
457 Although MS technological methods have become increasingly sensitive to detecting small molecules,
458 isobaric metabolites are often difficult to distinguish from one another. This is the case not only for several
459 metabolic intermediates of glycolysis, but also to additional metabolic pathways. An advantage to the in

460 silico mechanistic modeling of metabolic networks, is the ability to represent such metabolites as individual
461 entities investigating distinct metabolic reactions and the dynamics of each metabolite providing a more in-
462 depth observation of the intracellular interactions.

463 The need for models to be informed from and then simulate data using metabolomics sources
464 represents a significant advance in future possibilities of the use of this approach. With the small-scale
465 investigation and advanced and large-scale experimental biology, computers have become pivotal in not
466 only managing data but also in understanding the biological significance of the results and developing
467 further hypotheses for future research. Due to the ability to change variables and quickly analyze the
468 resulting metabolic effects, investigators can then simulate the effects of drugs or mutation on such
469 processes. In all, the ability to accurately and quickly simulate intracellular and intra-tissue pathways
470 represents a considerable leap forward in the ability to understand central biochemical underpinnings of
471 cellular life. The advancement of technology in both experimental biology and computational systems has
472 allowed scientific discovery and investigation on the chemical level. Elucidation of intracellular metabolite
473 and chemical dynamics can provide valuable insight into how cells utilize cellular components to grow,
474 respond to environmental stimuli, and ultimately support life. While deterministic models are able to
475 describe glucose metabolism and metabolic systems in general, we believe queueing theory may have the
476 potential to more realistically describe metabolic behavior by providing stochasticity to the pathway. In
477 summary, the current study presents the application of queueing theory as a beneficial modeling approach in
478 simulating metabolic pathway dynamics and predicting the effects of pharmacological inhibition.

479

480 **Acknowledgments**

481 The following support is acknowledged: NIH GM103427 (PHD), and the University of Nebraska at
482 Omaha Office of Research and Creative Activities FUSE and GRACA program (EC). This work utilized the
483 Holland Computing Center of the University of Nebraska, which receives support from the Nebraska
484 Research Initiative.

References

- 485 1. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 2000 Jan
486 1;28(1):27–30.
- 487 2. Hahl SK, Kremling A. A Comparison of Deterministic and Stochastic Modeling Approaches for
488 Biochemical Reaction Systems: On Fixed Points, Means, and Modes. *Front Genet* [Internet]. 2016
489 Aug 31 [cited 2017 Jun 26];7. Available from:
490 <http://journal.frontiersin.org/Article/10.3389/fgene.2016.00157/abstract>
- 491 3. Rapoport TA, Heinrich R, Rapoport SM. The regulatory principles of glycolysis in erythrocytes in
492 vivo and in vitro. A minimal comprehensive model describing steady states, quasi-steady states and
493 time-dependent processes. *Biochem J.* 1976 Feb 15;154(2):449–69.
- 494 4. Voit EO. The best models of metabolism: The best models of metabolism. *Wiley Interdiscip Rev Syst*
495 *Biol Med.* 2017 May 19;e1391.
- 496 5. Puchalka J, Kierzek AM. Bridging the Gap between Stochastic and Deterministic Regimes in the
497 Kinetic Simulations of the Biochemical Reaction Networks. *Biophys J.* 2004 Mar;86(3):1357–72.
- 498 6. Cao Y, Petzold L. Slow-scale tau-leaping method. *Comput Methods Appl Mech Eng.* 2008
499 Aug;197(43–44):3472–9.
- 500 7. Gillespie DT. Exact stochastic simulation of coupled chemical reactions. *J Phys Chem.* 1977
501 Dec;81(25):2340–61.
- 502 8. Ao P. Metabolic network modelling: Including stochastic effects. *Comput Chem Eng.* 2005
503 Oct;29(11–12):2297–303.
- 504 9. Kampen NG van. *Stochastic processes in physics and chemistry*. 3rd ed. Amsterdam ; Boston:
505 Elsevier; 2007. 463 p. (North-Holland personal library).
- 506 10. Kremling A, Bettenbrock K, Gilles E. Analysis of global control of Escherichia coli carbohydrate
507 uptake. *BMC Syst Biol.* 2007;1(1):42.
- 508 11. Lopez-Caamal F, Marquez-Lago TT. Order Reduction of the Chemical Master Equation via Balanced
509 Realisation. Kaderali L, editor. *PLoS ONE.* 2014 Aug 14;9(8):e103521.
- 510 12. Tyson JJ, Othmer HG. The Dynamics of Feedback Control Circuits in Biochemical Pathways. In:
511 *Progress in Theoretical Biology* [Internet]. Elsevier; 1978 [cited 2017 Jun 26]. p. 1–62. Available
512 from: <http://linkinghub.elsevier.com/retrieve/pii/B9780125431057500087>
- 513 13. Wu J, Vidakovic B, Voit EO. Constructing stochastic models from deterministic process equations by
514 propensity adjustment. *BMC Syst Biol.* 2011;5(1):187.
- 515 14. Massey WA. Asymptotic Analysis of the Time Dependent M/M/1 Queue. *Math Oper Res.* 1985
516 May;10(2):305–27.
- 517 15. Neuts MF, Chen S-Z. The Infinite-Server Queue with Poisson Arrivals and Semi-Markovian Services.
518 *Oper Res.* 1972 Apr;20(2):425–33.

- 519 16. Kendall DG. Stochastic Processes Occurring in the Theory of Queues and their Analysis by the
520 Method of the Imbedded Markov Chain. *Ann Math Stat.* 1953 Sep;24(3):338–54.
- 521 17. Sharp AT, Pannier AK, Wysocki BJ, Wysocki TA. A novel telecommunications-based approach to
522 HIV modeling and simulation. *Nano Commun Netw.* 2012 Jun;3(2):129–37.
- 523 18. Guo D, Zhang G, Wysocki TA, Wysocki BJ, Gelbard HA, Liu X-M, McMillan JM, Gendelman HE.
524 Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and
525 HIV clearance. *J Virol.* 2014 Sep 1;88(17):9504–13.
- 526 19. Martin T, Wysocki B, Wysocki T, Pannier A. Identifying Intracellular pDNA Losses From a Model of
527 Nonviral Gene Delivery. *IEEE Trans Nanobioscience.* 2015 Jan 23;
- 528 20. Evstigneev VP, Holyavka MG, Khrapaty SV, Evstigneev MP. Theoretical description of metabolism
529 using queueing theory. *Bull Math Biol.* 2014 Sep;76(9):2238–48.
- 530 21. Hochendoner P, Ogle C, Mather WH. A queueing approach to multi-site enzyme kinetics. *Interface*
531 *Focus.* 2014 Jun 6;4(3):20130077.
- 532 22. Jezewski AJ, Larson JJ, Wysocki B, Davis PH, Wysocki T. A novel method for simulating insulin
533 mediated GLUT4 translocation. *Biotechnol Bioeng.* 2014 Dec;111(12):2454–65.
- 534 23. Rao CV, Wolf DM, Arkin AP. Control, exploitation and tolerance of intracellular noise. *Nature.* 2002
535 Nov 14;420(6912):231–7.
- 536 24. Berg JM, Tymoczko JL, Stryer L, Stryer L. *Biochemistry.* 5th ed. New York: W.H. Freeman; 2002. 1
537 p.
- 538 25. Mulukutla BC, Yongky A, Daoutidis P, Hu W-S. Bistability in glycolysis pathway as a physiological
539 switch in energy metabolism. *PloS One.* 2014;9(6):e98756.
- 540 26. Infante G. Positive solutions of differential equations with nonlinear boundary conditions. 2003.
- 541 27. Erbe LH, Wang H. On the existence of positive solutions of ordinary differential equations. *Proc Am*
542 *Math Soc.* 1994 Mar 1;120(3):743–743.
- 543 28. Mathworks. Matlab Documentation- Choose an ODE Solver. [Internet]. Available from:
544 <http://www.mathworks.com/help/matlab/math/choose-an-ode-solver.html>
- 545 29. Schuster S, Fell DA, Dandekar T. A general definition of metabolic pathways useful for systematic
546 organization and analysis of complex metabolic networks. *Nat Biotechnol.* 2000 Mar;18(3):326–32.
- 547 30. Clement, EJ, Wysocki, BJ, Davis, PH, Wysocki, TA. On a Queueing Theory Method to Simulate In-
548 Silico Metabolic Networks. *Curr Metabolomics.* 2017;5.
- 549 31. Wysocki BJ, Martin TM, Wysocki TA, Pannier AK. Simulation supported estimation of end-to-end
550 transmission parameters in non-viral gene delivery. In *IEEE*; 2014 [cited 2016 Sep 29]. p. 4179–83.
551 Available from: <http://ieeexplore.ieee.org/lpdocs/epic03/wrapper.htm?arnumber=6883976>
- 552 32. Levy Y. Introduction to queueing theory, 2nd ed., by Robert B. Cooper, Elsevier North Holland, New
553 York, 1981, 347 pp. *Networks.* 1983;13(1):155–6.

- 554 33. Degenring D, Röhl M, Uhrmacher AM. Discrete event, multi-level simulation of metabolite
555 channeling. *Biosystems*. 2004 Jul;75(1–3):29–41.
- 556 34. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide
557 phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
558 *Cancer Res*. 2003 Nov 1;63(21):7436–42.
- 559 35. Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken
560 RA, Boothman DA. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective,
561 PAR-independent metabolic catastrophe and cell death induced by β -lapachone. *Cell Death Dis*. 2015
562 Jan 15;6(1):e1599.
- 563 36. Tan B, Young DA, Lu Z-H, Wang T, Meier TI, Shepard RL, Roth K, Zhai Y, Huss K, Kuo M-S,
564 Gillig J, Parthasarathy S, Burkholder TP, Smith MC, Geeganage S, Zhao G. Pharmacological
565 Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD⁺
566 Biosynthesis, in Human Cancer Cells: METABOLIC BASIS AND POTENTIAL CLINICAL
567 IMPLICATIONS. *J Biol Chem*. 2013 Feb 1;288(5):3500–11.
- 568 37. Tolstikov V, Nikolayev A, Dong S, Zhao G, Kuo M-S. Metabolomics Analysis of Metabolic Effects
569 of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibition on Human Cancer Cells. Campos-
570 Olivas R, editor. *PLoS ONE*. 2014 Dec 8;9(12):e114019.

571 **Supporting Information**

572 **S1. Pseudo Code.**

573 **S2. Kinetic Constants and Parameters of the model.**

574 **S3. Rate Equations used in the model.**

575 **S4. Maximal Velocities.**

576 **S5. Rate Files**

Table 1. Initial Concentrations of Glycolytic Metabolites

Metabolite	Concentration(mM)	Reference
GLC	5.0	[1]
G6P	0.039	[1]
F6P	0.013	[1]
F1,6BP	0.00231	[1]
F2,6BP	0.004	[3]
DHAP	0.02	[2]
GAP	0.00194	[2]
1,3BPG	0.000369	[1]
3PG	0.069	[1]
2PG	0.01	[1]
PEP	0.017	[1]
PYR	0.0586	[1]

Intracellular concentrations for each metabolic intermediate. The metabolite concentrations (millimolar) are used in each simulation to initiate the model and are allowed to change over the course of the simulation.

1. Mulquiney PJ, Kuchel PW. Model of 2,3-bisphosphoglycerate metabolism in the human erythrocyte based on detailed enzyme kinetic equations: equations and parameter refinement. *Biochem J.* 1999 Sep 15;342 Pt 3:581–96.
2. König M, Bulik S, Holzhütter H-G. Quantifying the contribution of the liver to glucose homeostasis: a detailed kinetic model of human hepatic glucose metabolism. *PLoS Comput Biol.* 2012;8(6):e1002577.
3. du Preez FB, Conradie R, Penkler GP, Holm K, van Dooren FLJ, Snoep JL. A comparative analysis of kinetic models of erythrocyte glycolysis. *J Theor Biol.* 2008 Jun 7;252(3):488–96.

Table 2. Additional Metabolites and Energy Nucleotides

Metabolite	Concentration(mM)	Reference
MgATP	1.52	[1]
MgADP	0.11	[1]
NAD	0.0599	[1]
NADH	0.000245	[1]
Pi	1.0	[1]
Mg	0.4	[1]
ATP	0.159	[1]
ADP	0.0937	[1]
AMP	0.03	[1]
H+	0.0000721	[2]
2,3BPG	3.1	[1]
GSH	3.2	[1]
ALA	0.2	[3]
G16BP	0.106	[1]

Intracellular concentrations required for rate equation calculations. The following metabolites influence the kinetics of the reactions yet were held constant for simulations to directly highlight concentration changes seen in glycolytic intermediates.

1. Mulquiney PJ, Kuchel PW. Model of 2,3-bisphosphoglycerate metabolism in the human erythrocyte based on detailed enzyme kinetic equations: equations and parameter refinement. *Biochem J.* 1999 Sep 15;342 Pt 3:581–96.
2. König M, Bulik S, Holzhütter H-G. Quantifying the contribution of the liver to glucose homeostasis: a detailed kinetic model of human hepatic glucose metabolism. *PLoS Comput Biol.* 2012;8(6):e1002577.
3. Groen AK, Sips HJ, Vervoorn RC, Tager JM. Intracellular compartmentation and control of alanine metabolism in rat liver parenchymal cells. *Eur J Biochem FEBS.* 1982 Feb;122(1):87–93.

bioRxiv preprint doi: <https://doi.org/10.1101/336677>; this version posted June 1, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.